DigiPath, Blue Line sign preferred supplier marketing and resource-sharing agreement

NewsGuard 100/100 Score

DigiPath, Inc. (OTCQB: DIGP), the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group. The agreement was designed to create synergies between Blue Line's cannabis industry protection, compliance and transportation services, and DigiPath Labs' testing and analytical services of cannabis-based products and media distribution.

In this cooperative relationship, DigiPath Labs and Blue Line are expected to share certain resources in Colorado and other states where both companies will operate. Blue Line and DigiPath have also agreed to promote each other as a "preferred vendor" through direct product and service referrals and through advertisements on Blue Line Smart Ads, the revenue-generating interactive displays available for free to marijuana-related businesses.

"We're excited to be partnering with Blue Line, an established and well respected company in the cannabis space," said DigiPath Inc.'s CEO Todd Denkin. "We look forward to a symbiotic relationship of providing services for the cannabis industry, from a testing perspective, from a media distribution perspective, and from a patient security perspective."

This pooling of resources is expected to benefit customers of both companies by reducing costs and saving time.

"Combining our compliance, security and transportation services with DigiPath's reliable safety and potency tests will streamline the supply chain," explained Sean Campbell, Blue Line's Chief Executive Officer. "Everyone wins in this partnership, including dispensaries, growers, product producers, and patients."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advancing computational pathology with UNI and CONCH foundation models